Advanced Melanoma Clinical Trials

16 studies are recruiting for advanced melanoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

   The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   NYU Langone Health, New York, New York

   Run by

   NYU Langone Health

   See if you can join NCT07504796 on ClinicalTrials.gov

2. High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

   The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy. The names of the groups in this research study are: * High-Intensity Exercise (EX) * High…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Locations

   2 in total

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT06298734 on ClinicalTrials.gov

3. Sitagliptin With Pembro in RCC and Melanoma

   This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped responding to prior PD-1 or PD-L1 immunotherapy. The study has two parts…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   University of Iowa, Iowa City, Iowa

   Run by

   Fernando Maciel Barbosa

   See if you can join NCT07634380 on ClinicalTrials.gov

4. Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

   This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT05629546 on ClinicalTrials.gov

5. VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

   This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease progressed on an anti PD-1 and an anti-CTLA-4 containing regi…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Banner MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   81 in total

   Run by

   Replimune, Inc.

   See if you can join NCT06264180 on ClinicalTrials.gov

6. AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

   This study is a first-in-human, open-label, nonrandomized, single center Phase 1 dose-escalation study to assess the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor activity of AB821 monotherapy given every 2 weeks (Q2W) or every 3 weeks (Q3W) in participants w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT07027488 on ClinicalTrials.gov

7. Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

   This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   OHSU Knight Cancer Institute, Portland, Oregon

   Run by

   OHSU Knight Cancer Institute

   See if you can join NCT07405086 on ClinicalTrials.gov

8. IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

   To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05039801 on ClinicalTrials.gov

9. A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

   The purpose of this study is to test whether the combination of fianlimab, cemiplimab, and ipilimumab is a safe and effective treatment that causes few or mild side effects for locally advanced or metastatic, unresectable, refractory melanoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Cedars-Sinai Medical Center, Los Angeles, California

   Locations

   12 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06594991 on ClinicalTrials.gov

10. Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

    The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Ironwood Cancer & Research Centers, Chandler, Arizona

    Locations

    107 in total

    Run by

    Eikon Therapeutics

    See if you can join NCT06697301 on ClinicalTrials.gov

11. At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

    This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic in Florida, Jacksonville, Florida

    Locations

    2 in total

    Run by

    Mayo Clinic

    See if you can join NCT05969860 on ClinicalTrials.gov

12. Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

    The purpose of this study is to determine if neoadjuvant (treatment before surgery) immunotherapy treatment based on tumor biomarkers results in better participant outcomes. Immunotherapy is the treatment of disease by using a person's own immune system. This study is divided into 2 sub-studies/par…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06295159 on ClinicalTrials.gov

13. Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

    The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care [SoC], best supp…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mayo Clinic Arizona, Phoenix, Arizona

    Locations

    82 in total

    Run by

    Immunocore Ltd

    See if you can join NCT05549297 on ClinicalTrials.gov

14. IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

    This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated advanced melanoma.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Arizona, Tucson, Arizona

    Locations

    211 in total

    Run by

    Immunocore Ltd

    See if you can join NCT06112314 on ClinicalTrials.gov

15. FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

    This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT06472661 on ClinicalTrials.gov

16. Naltrexone and Propranolol Combined With Immunotherapy

    Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral components of the body's response to stress. Pre-clinical studies have …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

    Run by

    Sarah Weiss

    See if you can join NCT05968690 on ClinicalTrials.gov